However, McClean and colleagues have thoroughly explored the anti‐AD effect of liraglutide in various prophylactic and AD‐induced APP/PS1 mice models and validated the therapeutic efficacy of this GLP‐1 analog. Here, APP is linked to Alzheimer disease.